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Alzheimer’s disease (AD) is a mental impairment and neural degeneration which causes progressive loss of memory and cognitive 
functions. This age‑dependent illness is associated with extracellular amyloid plaques accumulation and twisted neurofibrillary 
tangles. Amyloid plaques are experimentally generated in animal models in order to investigate the disease process. In this 
study, we followed a  rat model of AD for over a  year. Wistar rats were divided randomly into two groups as control group 
(surgery without injection Aβ), and experimental group (two‑sided intrahippocampal amyloid‑beta injection into hippocampus). 
From each group, three animals were investigated 42 days after injection, and the remaining four animals were studied after 
one year. All animals were tested for learning abilities and memory. Finally, samples from blood, brain, heart, kidney, liver, colon 
and spleen were examined. In the experimental group, the size of amyloid plaques were increased significantly after one year 
and learning abilities and memory were concomitantly decreased. Onsets of various other conditions such as liver and kidney 
disorders, diabetes, and metabolic syndrome were observed, which indicates that the animals may be prone to cardiovascular 
disorders and ischemia. 
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INTRODUCTION
Irreversible loss of memory and cognitive functions 
are associated with Alzheimer’s disease (Duleu et al. 
2010). The symptoms begin with short‑term memory 
loss and evolve toward time and space confusion, de‑
pression, speech disorders (aphasia), withdrawal, mood 
change, mental problems, and respiratory disorders 
(Alzheimer’s Association 2010, Rainon et al. 2016). Ab‑
normal formation and accumulation of Aβ peptides and 
tau proteins in the brain are two important neuropatho‑
logical features of Alzheimer’s disease (AD), with micro‑
scopic features such as neuritic plaques and intracel‑
lular neurofibrillary tangles, respectively (Davies et al. 
2009). These deposits formation is associated with dam‑
age to the brain blood vessels and synapses, lack of neu‑
rotransmitters, death of neurons, and loss of memory 
and learning problems (Frozza et al. 2009). In addition, 
AD reduces the brain blood flow speed (Hamel et al. 2004, 
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Iadecola et al. 2004), which is due to Aβ deposit on the 
vessels tunica, which reduces their elasticity (Petrella et 
al. 2003). In animal studies, intra‑hippocampal injection 
of Aβ has resulted in memory loss, learning problems, 
and cholinergic system dysfunction (Lu et al. 2009). 
Since 1993, numerous studies have been performed on 
animals in which AD was induced with beta‑amyloids of 
different lengths and other compounds such as strepto‑
zotocin, ibotenic acid and insulin amyloid fibrils (Cleary 
et al. 1995, Kheirbakhsh et al. 2015, Limón et al. 2012, Shi 
et al. 2011, Yaghmaei et al. 2013). 
Aβ is generated by the action of beta‑ and gamma‑ 
secretase enzymes on the amyloid precursor protein 
(APP). It has an oxidative activity which increases ab‑
normal active oxygen and nitrogen, while decreasing 
endogen antioxidants, and causing neurons degenera‑
tion (Yan et al. 2014).
Reactive oxygen species and oxidative stress are 
known mediators in neurodegenerative disorders af‑
fecting the brain function, and cause lipids and proteins 
oxidation and cellular damage in the central nervous 
system. On the other hand, insulin signal pathway is im‑
portant for regulating feeding behaviors and cognitive 
functions (Jhoo et al. 2004). Decrease of insulin levels in 
the brain and central nervous fluids and impairments in 
the insulin receptors function have been reported in AD 
patients (Hoyer et al. 2000). Increase in the blood sugar 
level, which cause oxidative stress and lipid peroxidation 
in some brain regions including hippocampus, is a result 
of disturbance in neuronal insulin signals. These facts 
demonstrate that there is a close relationship between 
AD and diabetes (Lupien et al. 2003, Sima et al. 2005). 
Amyloid plaques contain other proteins in addition 
to Aβ, such as Apolipoprotein E (APOE) which is encoded 
by another AD developing gene (Duleu et al. 2010). Apo‑
lipoprotein E4 is the main genetic risk factor of AD and 
cause high accumulation of amyloids in the brain before 
AD symptoms appearance (Polvikoski et al. 1995).
In this study, we compared the amyloid plaques den‑
sity in the beginning of AD, and one year after intrahip‑
pocampal injection of Aβ in animal model. Our main aim 
was to observe an AD model for a relatively long period 
in order to assess its characteristics over the long run. To 
this end, hematologic and blood biochemistry parame‑
ters, brain and vital organs histopathology, and memory 
loss were assessed during one year.
METHODS
Animals and experimental groups
The study was carried out in accordance with the Eu‑
ropean Communities Council Directive of 22 September, 
2010 (2010/63/EU) for care of laboratory animals and 
after approval of the Local Ethic Committee of Tehran 
University of Medical Sciences. 
Fourteen male Wistar rats (6 months old at the time of 
surgery, 250–300 g, from Pasteur Institute of Iran) were 
used in this study. Animals were housed in a pathogen‑ 
and temperature‑controlled (22±2) room with a constant 
12‑h light/dark cycle where they had access to food and 
water ad libitum. 
Animals were divided into control and Aβ‑treat‑
ed group with 7 animals in each group. Forty two days 
after surgery, 3 animals from each group were chosen 
randomly to examine the disorder occurrence. The re‑
maining were tested for histology, hematology, and bio‑
chemistry characteristics after one year.
Surgery and amyloid beta injection 
To 100 μg Aβ1‑42 (purchased from Sigma, St Lou‑
is, MO, USA), 100 μl PBS was added and incubated for 
seven days at 37°C. The resulting amyloid fibrils, which 
are neurotoxic (Goryacheva et al. 2010) were injected 
bilaterally in CA1 region of rats hippocampus. Two μl 
of Aβ1‑42 peptide was injected slowly with Hamilton 
syringe (Hamilton, USA) at each side with the help of 
a stereotaxic apparatus (SR‑6N Narishig, Japan) (Cal‑
abrese et al. 2000), and at coordinates indicated in the 
Paxinos atlas (Paxinos et al. 2007). The used coordinates 
were: anterior‑posterior (AP)=–4.8 mm, medial‑lateral 
(ML)=±3.5 mm, and dorsal‑ventral (DV)=–4 mm. Rats were 
first anesthetized by injection of ketamine (50 mg/kg, 
Alfasan) and xylazin (5 mg/kg, Woerden‑Holland). In the 
control group, empty syringe was used. Animals were 
then given 5–7 days recovery time.
Fig. 1. Comparing delay times to enter the dark compartment after 5 min in 
the test day in the initial stages of AD and during a year post AD induction. 
*** (P<0.001) * (P<0.05) (The Control group was evaluated after 42 days).
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Passive avoidance apparatus (shuttle box)
The shuttle box consisted of a light and a dark com‑
partment of the same size (20×20×30 cm each), separated 
by a retractable door (7×9 cm). Behavioral measurements 
were carried out at 42, 145, 320, 365 days and one year after 
surgery. In each measurement, animals were trained one 
day and tested the next day (Everss et al. 1998). In training 
step, each animal was put in the lightened section of the 
box for 5 seconds. The door was opened after what the an‑
imal could enter the dark section. After entrance the door 
was closed immediately, and the animal was allowed to ex‑
plore the dark part for 10 s. The procedure was repeated 
after 30 s, but the animal received electrical stimulation 
from the dark compartment floor for 5 s. The procedure 
was repeated with 2 min intervals until the animal showed 
a delay before entering the dark part. That delay was con‑
sidered as a sign of successful learning. On the test day, 
electrical stimulation was not applied. Animals were posi‑
tioned in the lightened section, the door was opened after 
5 s, and the delay duration before entering the dark section 
was recorded as a criterion for memorizing. The maximum 
allowed delay was 300 s (Urban et al. 1995).
Histology and hematological study
365 days after Aβ injection, remaining animals were 
anesthetized by intraperitoneal injection of ketamine 
and xylazine (60 and 20 mg/kg body weight, respec‑
tively). Cardiac puncture was then performed to make 
a terminal blood collection for hematologic and bio‑
chemistry measurements. Vital organs such as brains, 
hearts, kidneys, livers, colons, and spleens were ex‑
cised and kept in a solution of 10% formalin. Six µm 
thick sections were prepared from the samples. Brain 
tissues were stained using Thioflavin S (Sigma and St 
Louis, MO, USA) for fluorescence microscopy while oth‑
er tissues were stained with haematoxylin and eosin 
for routine light microscopy evaluations.
Data analysis
Results were expressed as mean ±S.E.M. In order to 
make multiple comparisons between groups, ANOVA 
method followed by Tukey’s post hoc test were used, with 
p<0.05 taken as statistically significant. In the case of in‑
sulin levels, Independent Samples t‑Test was used. 
RESULTS
Evaluation of the shuttle box test data
Comparison of the animals delay times to enter the 
dark chamber showed that the longer the disease per‑
sisted, the more impairment of learning and memory 
was observed. Delay time’s data corresponding to days 
365 and 320 following induction of AD were different 
Fig. 2. Hematology parameters of the animals, one year after AD induction. For statistical analysis, Anova method followed by Tukey’s post hoc test was used. 
WBC: White blood cell, LYMPH: Lymphocyte, Neut: Percentage of neutrophils, RBC: red blood cell, HGB: Hemoglobin, HCT: Compact RBC volume, MCV: The 
average blood cell volume, MCH: Mean weight of hemoglobin in a red blood cell, MCHC: Mean concentration of hemoglobin in red blood cells, RDW‑CV: The 
range of red blood cell size changes, P‑LCR: The ratio of large platelets, PLT: Platelet, PDW: Scale of platelet volume, MPV: Average platelet volume.
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at the most significance level (p<0.001) in comparison 
with day 42. Data of day 365 after AD induction also 
demonstrated significant change in comparison to the 
control group (p<0.05) (Fig. 1). In other words, reten‑
tion time of short‑term memory is decreased during 
one year, which is indicative of the upward progression 
of the disease. 
Hematology and biochemistry results
Evaluation of hematology factors and com plete 
blood count with differential (CBC‑Diff) after one year 
did not show any significant difference in the AD rats 
(Fig. 2). However, evaluation of the biochemical fac‑
tors of serum indicated marked changes. According to 
the statistical analysis, triglyceride (TG), hepatic en‑
zyme, aspartate aminotransferase (AST or OT1), and 
glucose (Glue) level demonstrated highly significant 
change compared to the control group (p<0.001). Alka‑
line phosphatase (ALP1) and alanine aminotransferase 
(ALT) also indicated marked differences compared to 
the control group (Fig. 3). Further, insulin hormone in‑
creased compared to the control group (Fig. 4).
Histology results
Comparison of the brain tissues of animals one year 
post AD induction with the day 42 tissues demonstrated 
increase in size of the amyloid plaques (Fig. 5). It should 
be mentioned that higher brightness of the plaques 
states the increased concentration of beta amyloid, and 
is indicative of neural pathways disturbance and ex‑
acerbation of the disease (Fig. 5). Assessment of other 
tissues illustrated notable disorders. In liver and kidney 
of animals, amorphous deposits resulting from amyloid 
bodies were observed (Fig. 6). In these tissues, inflamma‑
tion and changes in blood vessels are observed: monoc‑
ular inflammatory cells are found between hepatocytes 
(Fig. 6A‑1), and abnormal congested blood vessels are 
detected (Fig. 6A‑2).
DISCUSSION
The present study results demonstrated that Aβ in‑
jection in the CA1 regions of both brain’s hemispheres 
in Wistar rats causes memory loss and amyloid plaques 
formation which are exacerbated over time. Aβ‑treated 
group (experimental group) showed significant differ‑
ence in learning and memory capabilities, as demon‑
strated by decreased entrance delay in shuttle‑box test 
with respect to control group, both in the early days af‑
ter injection and later. In addition, histological analysis 
confirmed the presence of amyloid plaques which is an 
important characteristic of Alzheimer’s disease (Selkoe 
et al. 2016). 
In 1991, Aβ deposits were hypothesized to be the 
main cause of AD (Hardy and Allsop 1991). The 4 kDa 
beta‑amyloid peptide with 42–43 amino acids is derived 
from APP (Hardy and Allsop 1991). APP is expressed in 
Fig. 3. Biochemical evaluation of the animals, one year after AD induction. For statistical analysis, Anova method followed by Tukey’s post hoc test was 
used. URE1: Urea, CR1: Creatinine, ALP1: Alkaline phosphatase, OT1(AST): Aspartate aminotransferase, PT1(ALT): Alaninetransaminase, Glue: Glucose, 
Choles: Cholesterol, TG: Triglyceride, Mg: Magnesio, AlBumio: Albomin, GGT: Gamma‑Glutamyl Transferase, TP1: Total protein, BIlRu.D: Bilirubina Direct, 
K: Potassium, Amon: Ammonia, HDL and LDL: High and Low‑density lipoprotein.
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nervous system cells and involved in cytoskeleton, ex‑
tracellular matrix, and cellular connectivity (Gandy et 
al. 2005). However, Aβ protein deposits cause inflam‑
mation, oxidative reactions, and neurodegeneration in 
the brain cortex and hippocampus (Stanga et al. 2016). 
Aβ activates microglia and astrocytes, causing reac‑
tive oxygen generation and nitric oxide production 
resulting into neurons death (Vassar et al. 1999). Aβ 
1‑42 injection into brain gives rise to noticeable mem‑
ory impairment (Delgado et al. 2005), and is accompa‑
nied by hippocampal neurodegenerative alterations 
(Ceccom et al. 2012). In fact, memory impairment may 
start from hippocampus which is involved in learning 
(Choi et al. 2011, Ting et al. 2007). Overall, oxidative re‑
actions, inflammation, and neurodegeneration in the 
hippocampus and the cortex are considered to cause 
AD symptoms.
Accumulation of amyloids increases the distance be‑
tween neurons and interferes with connections (Frozza 
et al. 2009), which could be related with our observa‑
Fig.  4. Evaluating blood insulin of the AD animals, one year post AD 
induction. For statistical analysis, Independent Samples t‑Test was used.
Fig.  5. Comparing brain section of control group, AD animals following 42  days and 365  days post AD induction. Amyloid plaques are indicated by 
arrows. A and B: control groups. C, D and E: the animal brain tissue 42 days post AD induction and F, G and H, brain tissues 365 days post AD induction. 
Hippocampus area is shown with×40 magnification e.
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tions in both behavioral experiment, and histological 
tests performed one year after Aβ injection. Testing 
memory at days 120 and 365 shows a marked memory 
impairment compared with previous conducted tests; 
this downtrend of the graph columns is indicative of 
increasing memory deterioration associated with AD. 
Moreover, comparison of the images C, D, and E (42 days 
post AD induction) with images F, G and H (365 days post 
AD induction) illustrates considerable differences in the 
size of amyloid plaques and show increased neuronal ne‑
crosis (Fig. 5).
Besides direct damages in the brain, evaluation of 
blood and other tissues 365 days post AD induction 
demonstrated the occurrence of peripheral compli‑
cations. Glucose, TG, insulin and OT1 levels of the AD 
group clearly shows a significant change in comparison 
with the control group. The liver enzymes ALP1 and 
PT1 have also significantly changed which is sugges‑
tive of other tissues degeneration alongside with brain 
damage. 
Various conditions such as diabetes, mid‑life obesi‑
ty and vascular events are considered to increase the 
risk of AD occurrence (Fitzpatrick et al. 2009, Janson et 
al. 2004). Hence, factors such as elevated blood glucose 
levels or dyslipidemia may be considered as causative 
parameters in the disease. On the other hand, brain 
function damage may also lead to complications in oth‑
er organs. The idea that AD may actually be a systemic 
disease has been discussed at length in a recent review, 
where the authors point out the “chicken or egg” prob‑
lem when dealing with AD and the “whole body chang‑
es” that occur (Morris et al. 2014). Our results seem to 
be more in accordance with a causal effect of AD itself, 
which may somehow spread from the brain toward other 
organs. More exactly, what we see is a subsequent pe‑
ripheral effect of amyloid plaques initially injected in 
the brain. 
Further studies are needed to characterize the agents 
or pathways that are involved in this process. Based on 
previous studies, the role of oxidative stress is extremely 
important in AD (Tönnies and Trushina 2017).
In healthy condition, there is an equilibrium between 
active oxygen‑nitrogen species and anti‑oxygenation 
defense. When this equilibrated state is disturbed, oxi‑
dative stress occurs which impairs biological macromol‑
ecules such as extra‑ and intra‑cellular proteins, and cell 
membrane phospholipids. Oxidative stress is involved in 
many pathologies such as cardiovascular diseases, dia‑
Fig. 6. Comparison of animals liver (1) and kidney (2) tissues with control group one year after Aβ injection. (A) optical microscopy; tip of the arrows 
indicates necrotic lesions in the tissue. (A‑1) see monocular inflammatory cells, (A‑2) see congested blood vessels. (B) Fluorescence microscopy, arrows 
tips indicate amyloid deposits in the tissue. 
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betes, AD, and Parkinson (Afshari et al. 2007, Duleu et al. 
2010). Lipid peroxidation, which is caused by free radi‑
cals and changes the chemical characteristics, structure, 
and function of cell membranes plays also a role in neu‑
rodegenerative diseases (Kota et al. 2008).
Amyloid angiopathy may also occur in AD, result‑
ing into brain blood circulation decrease (Hamel et al. 
2004, Iadecola et al. 2004). Morphologic lesions relat‑
ed to beta amyloid accumulation in the brain vessels 
lead to decreased vasodilatation (Petrella et al. 2003). 
Damage to the brain vessels is followed by impairment 
of intracellular oxidative metabolism and consequent 
reduction in glucose, neurotransmitters, calcium and 
phosphate (Sultana et al. 2006). Ischemia and vascular 
obstruction result into a ten‑fold increase of free rad‑
ical production in the extracellular space of the hip‑
pocampal system and the basal ganglia (Magenta et 
al. 2013). The produced free radicals damage neuronal 
membrane and cause brain edema due to unsaturated 
fatty acids peroxidation in the membrane phospho‑
lipids; ultimately, neuronal death happens (Fujita et 
al. 2013).
In addition, a significant drop in brain glucose us‑
age has also been reported in AD. This abnormality oc‑
curs due to dysfunction of insulin neuronal signals. De‑
creased insulin concentration and functional perturba‑
tion of insulin receptors were observed in postmortem 
examination of the brain and cerebrospinal fluid of AD 
patients (O’Connell et al. 2013). Even though glucose 
transportation into the brain is not insulin dependent, 
insulin passage through blood‑brain barrier is linked 
to insulin receptors. Insulin receptors and insulin‑like 
factors are present in neurons and astrocytes, and hip‑
pocampus and hypothalamus which play main roles in 
learning and memory present the highest insulin re‑
ceptor density in the brain (Hoyer et al. 2000). In in‑
sulin‑resistant individuals, the cells do not respond in 
the normal way to insulin and glucose cannot easily en‑
ter the cells. As a consequence, more and more insulin 
has to be secreted to assist glucose transportation into 
cells, resulting into insulinemia. Finally, when the body 
is no longer able to produce enough insulin to maintain 
normal glucose levels, diabetic state occurs (Baker et 
al. 2011). 
In the present study, increased amounts of both glu‑
cose and insulin in the blood are indicative of insulin 
resistance in the brain cells. Glucose is the main energy 
source of the brain and its normal metabolism is neces‑
sary for accurate brain function and preserving cell en‑
ergy as ATP molecules. A decrease in glucose levels leads 
to problems in cognitive functions and affects the pro‑
cess of amyloid precursor proteins production which re‑
sults into higher accumulation of beta amyloid plaques 
(Rafacho et al. 2014).
Alongside with cholesterol, TGs constitute the plas‑
ma lipids. Elevated levels of blood TG, even in the ab‑
sence of other risk factors, are directly linked with high‑
er probability of cardiovascular pathologies, nephropa‑
thies and pancreatitis (Wenk et al. 1989). Increased blood 
TG is known to be one of main causes of metabolic syn‑
drome. Other key pathologic factors include increased 
insulin level in the blood (Clearfield et al. 2014, Nord‑
estgaard and Varbo 2014), hypertension, glucose toler‑
ance disorder, abdominal obesity (Yamaoka et al. 2014) 
and increased blood lipids. Besides two main health 
problems, namely diabetes and cardiovascular diseases, 
metabolic syndrome has numerous other consequences 
such as liver steatosis, cirrhosis, chronic kidney failure, 
albuminuria, hyperuricemia and gout, polycystic ovary 
syndrome, sleep apnea, cognitive disorder and dementia 
(Dietrich et al. 2014, Parapid et al. 2014).
Considerable increases were observed in the liver 
enzymes of the animal model of AD. The most sensitive 
and commonly used diagnostic liver enzymes are amino‑
transferases AST, OT1, and ALT (PT1) which are released 
into blood circulation upon liver damage. Consequently, 
elevation of these enzymes is indicative of widespread 
death of hepatocytes (hepatic necrosis)which is also ob‑
served in many inflammatory diseases (Choi et al. 2007, 
Raurich et al. 2015). High levels of aminotransferases 
have been reported in 90% of ischemic or toxic hepatic 
damages (Giboney 2005). A study indicated that in 98% 
of alcoholic hepatitis patients, blood AST level increased 
6–7 times compared to normal levels (Dufour et al. 2000). 
Moreover, patients with 10‑fold increase in their enzyme 
levels have been diagnosed with acute extrahepatic bile 
duct obstruction (Karim et al. 2015). Increased ALT and 
AST levels have been observed in 79% of hepatic cirrho‑
sis (Ferenci et al. 2003).
ALP1 is another enzyme which has increased in the 
AD model compared with healthy rats. It is a nonspe‑
cific enzyme with a widespread production in all tis‑
sues. High level of ALP1 is observed in kidney tubules 
and urologic disorders. Its levels rises in bone growth, 
malignancies, fracture repair, hepatic diseases, heart 
failure, over‑activity of parathyroid gland and many 
other diseases (Lucyk et al. 2015). Studies have shown 
that high rates of ALP1 play an important role in uro‑
logic disorders and prostate malignancies (Kamali et al. 
2010). In patients with prostate malignancy, high se‑
rum level of ALP1 is attributed to intensified bone me‑
tabolism which is indicative of metastasis to the bones 
(Lehmann et al. 2004). High ALP1 rate has been report‑
ed as a sensitive indicator of tubular damages in pa‑
tients with inflammatory bowel disease (IBD) who suf‑
fer also from kidney failure (Krones et al. 2015). More‑
over, studies have demonstrated that hepatic damage 
resulting from medicines consumption can emerge 
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with a cholestatic pattern or pathologic increase in 
ALP1 (Ghaznavi et al. 2005). Further, pathologic ALP1 
levels can also be related to metastatic lymphoma and 
liver cancers (Oorts et al. 2016, Pratt and Kaplan 2000).
In conclusion, one year after Aβ injection in the CA1 
regions of both hemispheres in Wistar rats, memory loss 
and Alzheimer’s plaques formation were seen. Other 
progressive pathologic events and disorders occurred 
in parallel with increased learning and memory impair‑
ments in liver and kidney of test animals. Based on the 
current results, AD state may be the cause of these pe‑
ripheral disorders, which would be of importance in AD 
patients’ condition. 
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